---
id: "entity-cleveland-clinic-d2"
type: "entity"
entityType: "organization"
canonicalName: "Cleveland Clinic"
aliases: []
source_timestamps: ["§ 4. Extend AMC research investments beyond early-stage science.", "¶18"]
tags: ["amc", "venture-capital"]
related: ["concept-amc-strategic-financing", "entity-khosla-ventures"]
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Cleveland Clinic

A major U.S. health system that launched a strategic collaboration with [[entity-khosla-ventures]], using its clinical environment as a **"sandbox"** for portfolio-company incubation and implementation. It is the article's canonical example of [[concept-amc-strategic-financing]] and of [[action-strategic-vc-partnerships]] (Pillar 4).

**Enrichment caveat:** the extraction's associated figure that **"$24 billion in nearly 700 companies"** was invested (attributed by the enrichment overlay to Cleveland Clinic; stated in the source as U.S. AMCs collectively) is **not supported** by the provided sources and should be treated as unverified until backed by primary institutional reporting.